Dual-listed biotech expects first-half revenue of CNY 936 million to CNY 946 million and net profit attributable to parent of CNY 236 million to CNY 246 million, both record highs.
Biocytogen forecast record first-half 2026 results, with revenue expected to exceed CNY 930 million for the first time and net profit attributable to owners of the parent projected to surge more than 390% from a year earlier. The company said operating revenue for the period is expected at CNY 936 million to CNY 946 million, up 50.80% to 52.41% from CNY 621 million in the same period of 2025. Net profit attributable to owners of the parent is forecast at CNY 236 million to CNY 246 million, compared with CNY 48 million a year earlier, implying growth of 391.87% to 412.71%. Non-recurring net profit is expected at CNY 192 million to CNY 202 million, up 574.02% to 609.04% from CNY 29 million. Biocytogen attributed the sharp increase to stronger demand in a global biopharmaceutical industry increasingly driven by innovation, alongside gains from its own technology offerings, service capabilities and customer network among global pharmaceutical and biotech companies. The company also said larger revenue scale and a stronger industry position are accelerating operating leverage, while lean management has helped lift gross margin and reduce the expense ratio. The preliminary forecast was disclosed on both the Shanghai and Hong Kong stock exchanges, where Biocytogen is listed as 688796.SS and 02315.HK. Final figures will be subject to the company’s 2026 semi-annual report.